ALNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alnylam Pharmaceuticals Inc (ALNY) is not a strong buy for a beginner, long-term investor at this time. While the company has promising growth in its RNAi platform and collaborations, the stock appears 'priced to perfection' with limited upside in the short term. Analysts' mixed ratings, recent price target downgrades, and declining financial metrics suggest caution. Additionally, no significant trading signals or congress trading data reinforce a hold stance.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 67.926. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. Key resistance is at 328.901, close to the current price, limiting immediate upside potential.
Collaborations with Viz.ai and the American Heart Association to enhance early diagnosis and patient care for ATTR-CM.
Strong revenue growth in Q4 2025 (up 84.95% YoY).
Positive sentiment in the options market with low put-call ratios.
Analysts' mixed ratings with multiple price target downgrades and concerns about the stock being 'priced to perfection.'
Declining financial metrics: Net income dropped by -322.56% YoY, EPS down -310.77% YoY, and gross margin decreased by -8.55% YoY.
Bearish moving averages and limited upside potential in the short term.
In Q4 2025, revenue increased significantly by 84.95% YoY to $1.097 billion. However, net income dropped by -322.56% YoY, EPS fell by -310.77%, and gross margin declined to 75.6% (-8.55% YoY), indicating profitability challenges despite revenue growth.
Analysts have mixed views. Jefferies downgraded the stock to Hold with a price target of $330, citing concerns about high valuation. Other firms like Canaccord and Freedom Capital maintain Buy ratings but have lowered price targets. Overall, analysts see long-term potential but express caution about near-term headwinds and valuation concerns.
